Clinical Trials Directory

Trials / Conditions / Diffuse Large B-cell Lymphoma Recurrent

Diffuse Large B-cell Lymphoma Recurrent

10 registered clinical trials studyying Diffuse Large B-cell Lymphoma Recurrent — 3 currently recruiting.

StatusTrialSponsorPhase
RecruitingGlofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
NCT06570447
Tianjin Medical University Cancer Institute and HospitalPhase 2
RecruitingCC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma
NCT06209619
Nathan DenlingerPhase 1
WithdrawnR-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or
NCT05966233
Fondazione Italiana Linfomi - ETSPhase 2
UnknownZanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
NCT06033820
RenJi HospitalPhase 2
RecruitingA-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL
NCT06086197
Zhejiang Cancer HospitalPhase 2
UnknownLenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL
NCT03795571
The First Affiliated Hospital with Nanjing Medical UniversityPhase 1
CompletedStudy to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Di
NCT03589469
ADC Therapeutics S.A.Phase 2
UnknownRICE-ibrutinib in Relapsed DLBCL
NCT02955628
Singapore General HospitalPhase 2
CompletedThe Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registr
NCT05169203
Herlev Hospital—
CompletedPhase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large
NCT01805557
Fondazione Italiana Linfomi - ETSPhase 2 / Phase 3